Bridget Cahill
Family · Laurel, MSNPI 1821044454
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 26.0% of the total. Reporting peaked in 2021 at $381 and has fallen 70.3% since, to $113 in 2025.
Across 70 payments — averaging $13.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$252
- Avion Pharmaceuticals$203
- Exeltis, USA Inc.$125
- Mayne Pharma Commercial LLC$116
- Organon$74
- Johnson & Johnson$45
- plus $153 from 7 others
What the payments were for
- Food & beverage$968100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $252 |
| Avion Pharmaceuticals | 20 | $203 |
| Exeltis, USA Inc. | 6 | $125 |
| Mayne Pharma Commercial LLC | 12 | $116 |
| Organon | 6 | $74 |
| Johnson & Johnson | 2 | $45 |
| Hologic Sales And Service, LLC | 2 | $31 |
| Therapeuticsmd, Inc. | 2 | $27 |
| Novo Nordisk | 1 | $23 |
| Pfizer | 1 | $23 |
| Millicent US Inc | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
How this compares
$968 in reported general payments places this provider in the 65th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 167 | $4,123 |
| Medroxyprogesterone Acetate | 49 | $881 |
| Ondansetron OdtOndansetron | 52 | $581 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 25 | $517 |
| ValacyclovirValacyclovir Hcl | 13 | $494 |
| Oxybutynin Chloride ErOxybutynin Chloride | 31 | $332 |
| Norgestimate-Ethinyl Estradiol | 11 | $239 |
| Fluconazole | 50 | $221 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $158 |
| Escitalopram Oxalate | 23 | $151 |
| Zolpidem Tartrate | 15 | $102 |
| Omeprazole | 12 | $73 |
Paid to pharmacies, not to this prescriber.
Other family in Laurel
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
- Ashley CocilovaFlowood$72K
- Andrea WallaceOlive Branch$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.